

RITA Medical Systems to Hold First Quarter 2005 Conference Call on May 10, 2005

MOUNTAIN VIEW, Calif., April 20 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (Nasdaq: RITA) today announced plans to release its financial results for the first quarter ended March 31, 2005, at 8:55 a.m. Eastern Time on Tuesday, May 10, 2005, and to host a conference call at 11:30 a.m. Eastern Time that same day.

Those interested in listening to the webcast of the RITA conference call may access the webcast via a link provided at the Company's website at www.ritamedical.com. Webcast participants will be able to submit a question to be considered for the question and answer period after logging in and clicking on the "Ask a Question" button provided on the webcast page.

Web participants are encouraged to go to the site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. An online replay of the call will also be available for one year immediately following the broadcast by accessing the same link.

About RITA Medical Systems, Inc.

RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone.

The statements in this news release related to the activities of professional societies in releasing news about the efficacy of radiofrequency ablation and the company's products are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.

SOURCE RITA Medical Systems, Inc.

04/20/2005

CONTACT: investors, Jill Bertotti of Allen & Caron Inc.,

+1-949-474-4300,

jill@allencaron.com,

for RITA Medical Systems, Inc.;

or Don Stewart, Chief Financial Officer,

dstewart@ritamed.com,

or Stephen Pedroff, VP Marketing Communications,

spedroff@ritamed.com,

both of RITA Medical Systems, Inc.,

+1-650-314-3400

Web site: <http://www.ritamedical.com>

(RITA)